Novavax expects COVID vaccine targetting Omicron in fourth quarter
The company's vaccine, based on an earlier strain of the virus, has not yet been authorised in the US, and is currently under FDA review
Novavax Inc said last week it expects to provide a COVID-19 vaccine targetting Omicron in the fourth quarter as it accelerates development of shots to protect against the BA.4 and BA.5 subvariants.
The US Food and Drug Administration (FDA) last week recommended COVID-19 vaccine manufacturers change the design of their booster shots beginning this fall to include components tailored to combat the currently dominant Omicron BA.4 and BA.5 subvariants.
Novavax expects additional pre-clinical data on shots tailored against the fast-spreading Omicron subvariants in late summer or fall.
The company’s vaccine, based on an earlier strain of the virus, has not yet been authorised in the US, and is currently under FDA review.
Edits by EP News Bureau